195 related articles for article (PubMed ID: 34139038)
1. Cardiovascular safety of vibegron, a new β3-adrenoceptor agonist, in older patients with overactive bladder: Post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
Neurourol Urodyn; 2021 Aug; 40(6):1651-1660. PubMed ID: 34139038
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
[TBL] [Abstract][Full Text] [Related]
3. Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.
Mitcheson HD; Samanta S; Muldowney K; Pinto CA; Rocha BA; Green S; Bennett N; Mudd PN; Frenkl TL
Eur Urol; 2019 Feb; 75(2):274-282. PubMed ID: 30661513
[TBL] [Abstract][Full Text] [Related]
4. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
5. International Phase III, Randomized, Double-Blind, Placebo and Active Controlled Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder: EMPOWUR.
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2020 Aug; 204(2):316-324. PubMed ID: 32068484
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study.
Varano S; Staskin D; Frankel J; Shortino D; Jankowich R; Mudd PN
Drugs Aging; 2021 Feb; 38(2):137-146. PubMed ID: 33469832
[TBL] [Abstract][Full Text] [Related]
7. Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial.
Staskin D; Frankel J; Varano S; Kennelly M; Newman DK; Rosenberg MT; Shortino DD; Jankowich RA; Mudd PN
Int J Clin Pract; 2022; 2022():6475014. PubMed ID: 35685566
[TBL] [Abstract][Full Text] [Related]
8. Once-Daily Vibegron 75 mg for Overactive Bladder: Long-Term Safety and Efficacy from a Double-Blind Extension Study of the International Phase 3 Trial (EMPOWUR).
Staskin D; Frankel J; Varano S; Shortino D; Jankowich R; Mudd PN
J Urol; 2021 May; 205(5):1421-1429. PubMed ID: 33356445
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of Vibegron in treating overactive bladder: A systematic review and pooled analysis of randomized controlled trials.
Shi H; Chen H; Zhang Y; Cui Y
Neurourol Urodyn; 2020 Jun; 39(5):1255-1263. PubMed ID: 32421908
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of novel β
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Hashimoto K; Minemura K
Int J Urol; 2019 Mar; 26(3):369-375. PubMed ID: 30557916
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of the novel β
Yoshida M; Kakizaki H; Takahashi S; Nagai S; Kurose T
Int J Urol; 2018 Jul; 25(7):668-675. PubMed ID: 29752752
[TBL] [Abstract][Full Text] [Related]
13. Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder.
Su S; Liang L; Lin J; Liu L; Chen Z; Gao Y
Medicine (Baltimore); 2021 Feb; 100(5):e23171. PubMed ID: 33592817
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Vibegron for the Treatment of Overactive Bladder in Women: A Subgroup Analysis From the Double-Blind, Randomized, Controlled EMPOWUR Trial.
Newman DK; Thomas E; Greene H; Haag-Molkenteller C; Varano S
Urogynecology (Phila); 2023 Jan; 29(1):48-57. PubMed ID: 36384907
[TBL] [Abstract][Full Text] [Related]
15. Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR.
Frankel J; Staskin D; Varano S; Kennelly M; Newman DK; Rosenberg MT; Jankowich RA; Shortino D; Mudd PN; Girman CJ
Adv Ther; 2022 Feb; 39(2):959-970. PubMed ID: 34921665
[TBL] [Abstract][Full Text] [Related]
16. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR).
Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR
Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
18. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder.
Ohlstein EH; von Keitz A; Michel MC
Eur Urol; 2012 Nov; 62(5):834-40. PubMed ID: 22695239
[TBL] [Abstract][Full Text] [Related]
20. Effects of vibegron, a novel β
Maruyama I; Yamamoto S; Tsuchioka K; Yamazaki T
Eur J Pharmacol; 2020 Jul; 878():173096. PubMed ID: 32259514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
